DGAP-News
HAEMATO AG - H1 2016: Sales growth 40% to EUR 142.27 million, EBIT-growth 40% to EUR 5.93 million, compared to prior year period
DGAP-News: HAEMATO AG / Key word(s): Half Year Results/Dividend
HAEMATO AG - H1 2016: Sales growth 40% to EUR 142.27 million, EBIT-growth
40% to EUR 5.93 million, compared to prior year period
29.08.2016 / 09:52
The issuer is solely responsible for the content of this announcement.
HAEMATO AG - H1 2016: Sales growth 40% to EUR 142.27 million, EBIT-growth
40% to EUR 5.93 million, compared to prior year period
29.08.2016 / 09:52
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Corporate News der HAEMATO AG:
H1 2016: Sales growth 40% to EUR 142.27 million, EBIT-growth 40% to EUR
5.93 million, compared to prior year period
In the second quarter 2016 HAEMATO AG, Berlin (ISIN: DE0006190705),
achieved IFRS Group sales of EUR 74.33 million (prior year period: EUR
56.16 million), a growth of 31.9% was achieved. The pleasant sales
achievement in the first quarter of EUR 67.94 million was run up by 9.4%.
In the first half-year HAEMATO achieved IFRS Group sales of EUR 142.27
million (prior year period: EUR 101.48 million), a growth of 40% was
produced.
The operating result (EBIT) increased as well by 40% to EUR 5.93 million
(prior year period: EUR 4.21 million). The annual general meeting was held
in June 2016. The shareholders decided again on a dividend pay of 30 Cent
per share.
"HAEMATO expanded sales from first quarter to second quarter. For the
following quarters we expect as well a good business development", says Dr.
Christian Pahl, Member of the Management Board of HAEMATO AG.
About HAEMATO:
HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the
business activities lies on the growth markets of patent free and patent
protected medicinal products. Focal points are therapies with cancer, HIV
and other chronic diseases.
HAEMATO AG is listed in the Entry Standard (Open Market) on the
Frankfurt Stock Exchange. Key figures for the share of HAEMATO AG:
Subscribed capital: EUR 20,778,898
Listed shares: ordinary shares
ISIN: DE000619070
WKN: 619070
Stock symbol: HAE
Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.de
---------------------------------------------------------------------------
29.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
496481 29.08.2016
Corporate News der HAEMATO AG:
H1 2016: Sales growth 40% to EUR 142.27 million, EBIT-growth 40% to EUR
5.93 million, compared to prior year period
In the second quarter 2016 HAEMATO AG, Berlin (ISIN: DE0006190705),
achieved IFRS Group sales of EUR 74.33 million (prior year period: EUR
56.16 million), a growth of 31.9% was achieved. The pleasant sales
achievement in the first quarter of EUR 67.94 million was run up by 9.4%.
In the first half-year HAEMATO achieved IFRS Group sales of EUR 142.27
million (prior year period: EUR 101.48 million), a growth of 40% was
produced.
The operating result (EBIT) increased as well by 40% to EUR 5.93 million
(prior year period: EUR 4.21 million). The annual general meeting was held
in June 2016. The shareholders decided again on a dividend pay of 30 Cent
per share.
"HAEMATO expanded sales from first quarter to second quarter. For the
following quarters we expect as well a good business development", says Dr.
Christian Pahl, Member of the Management Board of HAEMATO AG.
About HAEMATO:
HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the
business activities lies on the growth markets of patent free and patent
protected medicinal products. Focal points are therapies with cancer, HIV
and other chronic diseases.
HAEMATO AG is listed in the Entry Standard (Open Market) on the
Frankfurt Stock Exchange. Key figures for the share of HAEMATO AG:
Subscribed capital: EUR 20,778,898
Listed shares: ordinary shares
ISIN: DE000619070
WKN: 619070
Stock symbol: HAE
Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.de
---------------------------------------------------------------------------
29.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
496481 29.08.2016
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte